Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Seeing Clearly: A Decision Analysis of MRI and Biomarkers in Prostate Cancer

FY 2018-19

Summary
Seeing Clearly: A Decision Analysis of MRI and Biomarkers in Prostate Cancer Prostate cancer is the most common cancer amongst men in Canada affecting 1 in 7 individuals. MRI and biomarkers have revolutionized the approach to early stage prostate cancer detection, identifying prostate pathology in a clinically useful and reliable manner. Given the prevalence of prostate cancer, these findings are remarkably impactful to early stage and active surveillance patients. In particular, when MRI and biomarkers are used in combination, studies have reported an excellent ability to discriminate patients who do not harbour clinically significant disease from those who do. This avoids potential overtreatment in low risk individuals while properly risk stratifying high risk patients. However, choosing wisely is necessary in a resource limited setting like Canada. Both biomarker testing and MRI are expensive and not widely available. Their relation to and unintended consequences on other services will require infrastructure investment, funding reprioritization, and wait time assessments prior to widespread adoption. To date, no decision analyses have evaluated the effect of MRI and biomarkers on our healthcare system. Methods: We will create a decision analysis model to evaluate the clinical and cost-effectiveness of incorporating MRI and biomarker testing in primary prostate cancer detection, compared to standard of care, for the detection of clinically significant PCa, avoidance of clinically insignificant PCa, and biopsies saved. Our model will stratify clinically effective and cost effective approaches across a wide variety of patient, physician, and societal scenarios to inform broad-based policy decisions as well as individualized patient-level decisions.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406431
Name
Cheung Douglas
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Seeing Clearly: A Decision Analysis of MRI and Biomarkers in Prostate Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarkers; Cost Effectiveness; Decision Model; Detection; Mri; Prostate Cancer; Screening; Test Performance
Abstract
Seeing Clearly: A Decision Analysis of MRI and Biomarkers in Prostate Cancer Prostate cancer is the most common cancer amongst men in Canada affecting 1 in 7 individuals. MRI and biomarkers have revolutionized the approach to early stage prostate cancer detection, identifying prostate pathology in a clinically useful and reliable manner. Given the prevalence of prostate cancer, these findings are remarkably impactful to early stage and active surveillance patients. In particular, when MRI and biomarkers are used in combination, studies have reported an excellent ability to discriminate patients who do not harbour clinically significant disease from those who do. This avoids potential overtreatment in low risk individuals while properly risk stratifying high risk patients. However, choosing wisely is necessary in a resource limited setting like Canada. Both biomarker testing and MRI are expensive and not widely available. Their relation to and unintended consequences on other services will require infrastructure investment, funding reprioritization, and wait time assessments prior to widespread adoption. To date, no decision analyses have evaluated the effect of MRI and biomarkers on our healthcare system. Methods: We will create a decision analysis model to evaluate the clinical and cost-effectiveness of incorporating MRI and biomarker testing in primary prostate cancer detection, compared to standard of care, for the detection of clinically significant PCa, avoidance of clinically insignificant PCa, and biopsies saved. Our model will stratify clinically effective and cost effective approaches across a wide variety of patient, physician, and societal scenarios to inform broad-based policy decisions as well as individualized patient-level decisions.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cheung, Douglas
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~